FOSTER CITY, Calif. -- Sept. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Dynogen Pharma gets $50M round (TheDeal.com)
News | 04. 19. 2004
Dynogen Pharmaceuticals
Boston-based Dynogen Pharmaceuticals Inc. said Monday, April 19, it had secured a $50 million B round of financing that it will use to further develop its neuroscientific approach to treating genitourinary and gastrointestinal disorders.
